Adlai Nortye Ltd. American Depositary Shares (ANL) - Total Liabilities
Based on the latest financial reports, Adlai Nortye Ltd. American Depositary Shares (ANL) has total liabilities worth $64.12 Million USD as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Adlai Nortye Ltd. American Depositary Sh cash flow conversion to assess how effectively this company generates cash.
Adlai Nortye Ltd. American Depositary Shares - Total Liabilities Trend (2019–2024)
This chart illustrates how Adlai Nortye Ltd. American Depositary Shares's total liabilities have evolved over time, based on quarterly financial data. Check financial resilience of Adlai Nortye Ltd. American Depositary Sh to evaluate the company's liquid asset resilience ratio.
Adlai Nortye Ltd. American Depositary Shares Competitors by Total Liabilities
The table below lists competitors of Adlai Nortye Ltd. American Depositary Shares ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Kalekim Kimyevi Maddeler Sanayi & Ticaret AS
IS:KLKIM
|
Turkey | TL2.43 Billion |
|
Cigniti Technologies Limited
NSE:CIGNITITEC
|
India | Rs3.50 Billion |
|
Shanghai Challenge Textile Co Ltd
SHE:002486
|
China | CN¥210.33 Million |
|
Drugs Made In America Acquisition Corp. Ordinary Shares
NASDAQ:DMAA
|
USA | $7.36 Million |
|
Dynasty Ceramic Public Company Limited
BK:DCC
|
Thailand | ฿3.39 Billion |
|
Egis Technology
TWO:6462
|
Taiwan | NT$6.65 Billion |
|
Nu Skin Enterprises Inc
NYSE:NUS
|
USA | $624.61 Million |
|
Tcc Steel
KO:002710
|
Korea | ₩320.41 Billion |
Liability Composition Analysis (2019–2024)
This chart breaks down Adlai Nortye Ltd. American Depositary Shares's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Adlai Nortye Ltd. American Depositary Sh (ANL) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.03 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 8.10 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.89 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Adlai Nortye Ltd. American Depositary Shares's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Adlai Nortye Ltd. American Depositary Shares (2019–2024)
The table below shows the annual total liabilities of Adlai Nortye Ltd. American Depositary Shares from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $45.78 Million | -9.85% |
| 2023-12-31 | $50.79 Million | -83.82% |
| 2022-12-31 | $313.89 Million | -1.02% |
| 2021-12-31 | $317.11 Million | +88.42% |
| 2020-12-31 | $168.30 Million | +109.90% |
| 2019-12-31 | $80.18 Million | -- |
About Adlai Nortye Ltd. American Depositary Shares
Adlai Nortye Ltd., a clinical-stage biotechnology company, engages in the research and development of pharmaceutical products. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trials for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E recept… Read more